Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells.

Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Röcken M.

J Exp Med. 2011 Oct 24;208(11):2291-303. doi: 10.1084/jem.20100977. Epub 2011 Oct 10.

2.

A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.

Ghoreschi K, Mrowietz U, Röcken M.

J Mol Med (Berl). 2003 Aug;81(8):471-80. Epub 2003 Jul 18. Review.

PMID:
12879154
3.

Psoriasis and other Th17-mediated skin diseases.

Tokura Y, Mori T, Hino R.

J UOEH. 2010 Dec 1;32(4):317-28. Review.

PMID:
21226422
4.

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH.

Clin Exp Immunol. 2010 Oct;162(1):1-11. doi: 10.1111/j.1365-2249.2010.04143.x. Review.

5.

From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited.

Boniface K, Blom B, Liu YJ, de Waal Malefyt R.

Immunol Rev. 2008 Dec;226:132-46. doi: 10.1111/j.1600-065X.2008.00714.x. Review.

6.
7.

Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination.

Rostami A, Ciric B.

J Neurol Sci. 2013 Oct 15;333(1-2):76-87. doi: 10.1016/j.jns.2013.03.002. Epub 2013 Apr 8. Review.

8.

Dendritic cells in experimental allergic encephalomyelitis and multiple sclerosis.

Link H, Huang YM, Xiao BG.

J Neuroimmunol. 1999 Dec;100(1-2):102-10. Review.

PMID:
10695720
9.

Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines.

Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A.

Curr Rheumatol Rep. 2007 Dec;9(6):461-7. Review.

10.

Th17 Cells and autoimmune encephalomyelitis (EAE/MS).

Aranami T, Yamamura T.

Allergol Int. 2008 Jun;57(2):115-20. doi: 10.2332/allergolint.R-07-159. Review.

11.

Immune deviation strategies in the therapy of psoriasis.

Ghoreschi K, Röcken M.

Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):193-8. Review.

PMID:
15180473
12.

Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.

Quatresooz P, Hermanns-Lê T, Piérard GE, Humbert P, Delvenne P, Piérard-Franchimont C.

J Biomed Biotechnol. 2012;2012:147413. doi: 10.1155/2012/147413. Epub 2012 Jun 12. Review.

13.

Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease.

Sun L, He C, Nair L, Yeung J, Egwuagu CE.

Cytokine. 2015 Oct;75(2):249-55. doi: 10.1016/j.cyto.2015.01.030. Epub 2015 Mar 18. Review.

14.

Pathophysiology of interleukin-23 in experimental autoimmune encephalomyelitis.

Touil T, Fitzgerald D, Zhang GX, Rostami AM, Gran B.

Drug News Perspect. 2006 Mar;19(2):77-83. Review.

PMID:
16628262
15.

Targeting dendritic cells to treat multiple sclerosis.

Comabella M, Montalban X, Münz C, Lünemann JD.

Nat Rev Neurol. 2010 Sep;6(9):499-507. doi: 10.1038/nrneurol.2010.112. Epub 2010 Aug 17. Review.

PMID:
20717105
16.

Psoriasis and multiple sclerosis: is there a link?

Kwok T, Jing Loo W, Guenther L.

J Cutan Med Surg. 2010 Jul-Aug;14(4):151-5. Review.

PMID:
20642982

Supplemental Content

Support Center